TODAY'S MARKET INTELLIGENCE
Pharmaron Reports 2026 Interim Results: Net Profit Up 6.96% YoY
English summary
Pharmaron (300759.SZ) reported H1 2026 revenue of RMB 7.595 billion, up 17.92% YoY, and net profit attributable to shareholders of RMB 750 million, up 6.96% YoY. New orders grew over 30% YoY, with CDMO new orders up over 50%. No dividend or share transfer is planned.
The English text is machine translated and may require verification against the Chinese version.
Browse today's intelligence